Skip to main content
. Author manuscript; available in PMC: 2019 Jun 10.
Published in final edited form as: Oncogene. 2018 Dec 10;38(14):2595–2610. doi: 10.1038/s41388-018-0610-8

Fig 6. Loss of LATS1/2 inhibits MC38 tumor growth in xenografted mice.

Fig 6.

a-b: Deletion of LATS1/2 in MC38 cells inhibits tumor growth in vivo. MC38 WT and LATS1/2 deletion clone #5 (1×106 cells for each injection) were implanted subcutaneously into nude mice. Tumor volume was monitored and tumor weight determined at the end of the experiments. ** p<0.01, *** p<0.001. The p value of tumor volume was determined using two-way ANOVA test. The p value of tumor weight was Student’s t-test.

c: YAP phosphorylation is decreased in the LATS1/2 deleted tumors. Tumor samples (panel B) were harvested and then subjected to immunoblot analysis with indicated antibodies.

d: Increased expression of YAP/TAZ target genes in the LATS1/2 deleted tumors. RNA was isolated from tumor samples (panel B) and analyzed by RT-PCR for YAP/TAZ target genes. Normalized data are expressed relative to the corresponding value for WT tumors and are mean±SD; n=3 tumors for each group.

e: Loss of LATS1/2 decreases cell proliferation and increases apoptosis in MC38 tumors. Immunohistochemistry staining for YAP, cleaved caspase3, and p-Histone H3 in representative tumor tissue. Scale bar, 100 µm. Data are mean±SD from 5 independent fields. *** p<0.001; Student’s t-test was applied.